New Delhi: Hyderabad-based Aurobindo Pharma will collaborate with the Biotechnology Industry Research Assistance Council (BIRAC), set up by the Department of Biotechnology for the development of the COVID-19 vaccine, it announced on Tuesday.
BIRAC has facilitated the establishment of ‘the r-VSV vaccine’ manufacturing platform for the first time in India by supporting Aurobindo Pharma’s COVID-19 vaccine development, the company said in a regulatory filing, Hindustan Times (HT) reported quoting PTI.
Aurobindo Pharma is developing a COVID-19 vaccine through its wholly-owned US subsidiary, Auro Vaccines. The vaccine candidate is based on a proprietary vaccine delivery platform of the company, the report added.
“Aurobindo is in the process of setting up a state-of-art manufacturing facility for viral vaccines which will be used to produce the COVID-19 vaccine and other viral vaccines. The plant will comply with global standards. The company’s COVID-19 vaccine development is going as per plan,” the filing added.
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the pharma firms in India working on the coronavirus vaccine.
